Related Experiment Video

Updated: Aug 13, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR

Maud Barbado1, Laurence Preisser, Michele Boisdron-Celle

  • 1Laboratoire d'Oncopharmacologie, INSERM U564, Centre Paul Papin, 2 Rue Moll, 49 033 Angers Cedex, France.

Cancer Letters
|January 3, 2006
PubMed

Insights

Accurately quantifying cancer drug resistance factors like thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) is crucial. This study presents a novel real-time quantitative RT-PCR method for precise, simultaneous measurement from single tumor biopsies.

Area of Science:

  • Molecular Oncology
  • Pharmacogenomics
  • Biomarker Discovery

Background:

  • Pretherapeutic determination of tumor resistance to chemotherapy remains a significant clinical challenge.
  • Existing methods are limited by the number of mechanisms assessed, small sample sizes, technical heterogeneity, and lack of quantification.
  • Accurate assessment of drug resistance factors is essential for personalized cancer therapy.

Purpose of the Study:

  • To develop and validate a real-time quantitative RT-PCR (RT-qPCR) method for simultaneous determination of multiple cancer drug resistance transcripts.
  • To enable quantitative assessment of gene expression from a single cDNA sample derived from a tumor biopsy.
  • To establish a clinically applicable technique for evaluating resistance factors, exemplified by fluoropyrimidine resistance genes.

Main Methods:

  • A novel frame-shifted artificial construct was designed as an internal standard for real-time quantitative RT-PCR.
  • The method was validated by quantifying the expression of five key fluoropyrimidine resistance genes: thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine kinase (TK), dihydrofolate reductase (DHFR), and folylpolyglutamate synthetase (FPGS).
  • Gene expression was analyzed in tumor and adjacent normal mucosa tissue samples from 33 colorectal carcinoma patients.

Main Results:

  • The developed real-time quantitative RT-PCR technique, utilizing the artificial construct standard, provided accurate and comparable quantification of multiple resistance factors.
  • The method demonstrated suitability for analyzing gene expression from limited clinical specimens.
  • Expression levels of TS, DPD, TK, DHFR, and FPGS were successfully quantified in colorectal cancer samples.

Conclusions:

  • This real-time quantitative RT-PCR approach offers a robust and clinically relevant method for simultaneously assessing multiple cancer drug resistance factors.
  • The technique allows for precise quantification and comparison of resistance gene expression from a single tumor biopsy.
  • Further investigation in a control study will explore the utility of this approach for determining tumor resistance phenotypes.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Real Time RT-PCR02:57

Real Time RT-PCR

Real-time reverse transcription-polymerase chain reaction, or Real-time RT-PCR, is an analytical tool used to determine the expression level of target genes. The method involves converting mRNA to complementary DNA with the help of an enzyme known as reverse transcriptase, followed by the PCR amplification of the cDNA. These two processes can be performed simultaneously in a single tube or separately as a two-step reaction.
The real-time quantification of the number of amplified products is...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...